<DOC>
	<DOCNO>NCT00784732</DOCNO>
	<brief_summary>This study compare effectiveness QAV680 placebo treat symptom seasonal allergic rhinitis Environmental Exposure Chamber .</brief_summary>
	<brief_title>A Study Compare Efficacy QAV680 Against Placebo Treating Seasonal Allergic Rhinitis Environmental Exposure Chamber</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Positive skin prick test ragweed allergen FEV1 must ≥80 % predicted value screen prior entry EEC Day 2 . Patients must weigh least 50 kg , must body mass index ( BMI ) within range 18 35 kg/m2 . Nonsmokers exsmokers ( ≤10 pack year &gt; 6 month smoke abstinence ) . Understand sign write informed consent Patients require change use prescription drug within four ( 4 ) week prior initial dosing . Participation clinical investigation within four ( 4 ) week prior initial dose longer require local regulation , limitation participation base local regulation . Significant illness within two ( 2 ) week prior initial dosing . History immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result . A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Seasonal Allergic Rhinitis</keyword>
	<keyword>Environmental Exposure Chamber</keyword>
	<keyword>nasal lavage</keyword>
</DOC>